Meta AnalysisID 7229
谷氨酸能药物对强迫症及相关障碍的效果：系统评价和Meta分析
CRD42023472430
Effect of glutamatergic medications for obsessive-compulsive and related disorders: A systematic review and meta-analysis
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 7229
- Evidence Id
- 15787
- Core Evidence Id
- 15787
- Source Meta Analysis Id
- 7215
- Herb2 Meta Analysis Id
- HBMA007215
- Crd Id
- CRD42023472430
- Title
- Effect of glutamatergic medications for obsessive-compulsive and related disorders: A systematic review and meta-analysis
- Review Question
- Effect of glutamatergic medications for obsessive-compulsive and related disorders: A systematic review and meta-analysis
- Study Type Included
- Only double-blinded randomized control trials (RCTs) will be included.
- Condition Being Studied
- Obsessive-compulsive and related disorders (OCRD): Obsessive-compulsive disorder (OCD) Body dysmorphic disorder (BDD) Trichotillomania (hair-pulling disorder/trichobezoar) Excoriation disorder (skin-picking disorder) Hoarding disorder (pathological collecting) Substance/medication-induced OCRD OCRD due to another medical disorder Other specified OCRD Unspecified OCRD
- Participant
- Patients with any obsessive-compulsive and related disorders (OCRD) described as above regardless of age, sex, or refractoriness of OCRD.
- Animal
- Human Disease Modelled
- Intervention
- Glutamatergic medications: Lamotrigine Topiramate Gabapentin Memantine Amantadine Ketamine Esketamine Dextromethorphan Agmatine Minocycline N-acetylcysteine Glycine D-cycloserine Sarcosine L-carnosine Riluzole Modafinil
- Comparator Control
- Control: Placebo. Important observation: Patients can receive medications for OCRD, such as selective serotonin receptor inhibitors (SSRIs), clomipramine, and/or risperidone.
- Main Outcome
- Change in obsessive-compulsive and related disorders (OCRD) scores from baseline to the last available follow-up, measured in continuous scales including but not limited to: Yale-Brown Obsessive Compulsive (Y-BOCS) scale for obsessive-compulsive disorder symptoms and body dysmorphic disorder symptoms Massachusetts General Hospital Hairpulling scale for trichotillomania symptoms Massachusetts General Hospital Skin Picking scale for excoriation symptoms Saving Inventory-Revised for hoarding symptoms
- Outcome Measure
- Additional Outcome
- No additional outcomes.
- Study Method
- Meta-analysis, Systematic review
- Keyword
- MeSH headings have not been applied to this record
- Contact
- David Richer Araujo Coelho [email protected]
- Organisational Affiliation
- Master of Public Health in Clinical Effectiveness, Harvard T. H. Chan School of Public Health, Boston, MA, USA. Division of Neuropsychiatry and Neuromodulation, Massachusetts General Hospital, Boston, MA, USA.
- Funding Source
- None.
- Other Selection Criteria
- Final Publication
- Same Topic Review
- None.
- Published Protocol
- Review Type
- Language
- English
- Country
- United States of America
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-10-13
- Registration Date
- 2023-10-24
- Anticipated Start Date
- 2023-10-13
- Anticipated Completion Date
- 2024-01-31
- Title Cn
- 谷氨酸能药物对强迫症及相关障碍的效果：系统评价和Meta分析
- Title En
- Effect of glutamatergic medications for obsessive-compulsive and related disorders: A systematic review and meta-analysis
- Bilingual Status
- complete